<DOC>
	<DOC>NCT01313273</DOC>
	<brief_summary>The aim of the study is to compare in an exploratory fashion the efficacy on progression-free survival of lanreotide in addition to non steroidal anti androgens and LHRH-a in non metastatic castrate resistant prostate cancer patients.</brief_summary>
	<brief_title>Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients</brief_title>
	<detailed_description>LHRH-a=Luteinizing Hormone-Releasing Hormone Analogues</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<mesh_term>Estrogens, Conjugated (USP)</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Nonsteroidal Anti-Androgens</mesh_term>
	<mesh_term>Androgen Antagonists</mesh_term>
	<criteria>Histologically proven diagnosis of prostate cancer Evidence of PSA progression despite castrate levels of testosterone (&lt;50 ng/dL) following orchiectomy or during therapy with luteinizing hormone releasing hormone agonists (LHRHa) Patients with nonmetastatic or stable metastatic disease Chromogranin A elevation above normal range (confirmed by a second evaluation at least 1 week later) [cut off levels will be &gt; 20 U/L for enzyme linked immunosorbent (ELISA) assay and &gt; 100 ng/ml for immunoradiometric (IRMA) assay] Patients who according to the investigator opinion are candidates to be treated immediately with chemotherapy (e.g. docetaxel) First line treatment with antiandrogen in monotherapy Visceral metastasis Previous or concomitant treatment with a somatostatin analogue</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>